B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a five-year survival rate of approximately 5–10%. The immune checkpoint blockade represented by PD-1/PD-L1 inhibitors has been effective in a variety of solid tumors but has had little clinical response in pancreatic cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Li, Jie, Chen, Yue, Que, Ziting, Du, Jiawei, Zhang, Jianqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740860/
https://www.ncbi.nlm.nih.gov/pubmed/36499340
http://dx.doi.org/10.3390/ijms232315005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740860/
https://www.ncbi.nlm.nih.gov/pubmed/36499340
http://dx.doi.org/10.3390/ijms232315005

Ejemplares similares